Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
6 hedge funds and large institutions have $100K invested in Genetic Technologies Ltd. in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
2% less capital invested
Capital invested by funds: $103K → $100K (-$2.51K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$56.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.93K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$431 |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$60 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$12.1K |
| 2 |
SA
Scarborough Advisors
Annapolis,
Maryland
|
-$8.11K |
| 3 |
PWA
Provenance Wealth Advisors
Fort Lauderdale,
Florida
|
-$57 |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $83K | +$56.5K | +17,047 | +97% |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $9.05K | -$3 | -1 | -0% |
|
|
3
UBS Group
Zurich,
Switzerland
| $7.19K | +$9.93K | +2,994 | New |
|
|
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $960 | – | – | – |
|
|
5
Wells Fargo
San Francisco,
California
| $312 | +$431 | +130 | New |
|
|
TSS
6
Two Sigma Securities
New York
| – | -$12.1K | -3,169 | Closed |
|
|
SA
7
Scarborough Advisors
Annapolis,
Maryland
| – | -$8.11K | -2,128 | Closed |
|
|
PWA
8
Provenance Wealth Advisors
Fort Lauderdale,
Florida
| – | -$57 | -15 | Closed |
|
|
9
Simplex Trading
Chicago,
Illinois
| – | +$60 | +18 | New |
|
GENE Hedge Fund Activity: Q4 2023 in Review
6 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q4 2023, worth a combined $100K — down 2.4% from $103K a quarter earlier.
Fund positioning in GENE was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $56.5K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $12.1K sold.
- 6 institutional investors held Genetic Technologies Ltd. (GENE) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $100K of Genetic Technologies Ltd. stock for Q4 2023, down 2.4% quarter-over-quarter.
- 3 funds opened new Genetic Technologies Ltd. positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest Genetic Technologies Ltd. buyer in Q4 2023 was Morgan Stanley, an estimated $56.5K added.
- The largest Genetic Technologies Ltd. seller in Q4 2023 was Two Sigma Securities, an estimated $12.1K sold.
Based on aggregated 13F filings for Q4 2023.